Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJXDGC)

Drug Name
Cefaclor Drug Info
Synonyms
Alenfral; Alfacet; Alfatil; CCL; Ceclor; Cefaclorum; Distaclor; Kefolor; Panacef; Panoral; Alfatil Kapseln; Cefaclor anhydrous; Cefaclor hydrate; Cefaclor monohydrate; Dystaclor MR; Kefolor Suspension; Muco Panoral; Lilly 99638 hydrate; Alenfral (TN); Ceclor (TN); Cefaclor (JP15); Cefaclor (USP); Distaclor (TN); Keflor (TN); L-Kefral; Raniclor (TN); S-6472; Cefaclor-1-wasser; Cefaclor [USAN:INN:BAN:JAN]; Ceclor, Distaclor, Keflor, Raniclor, Cefaclor; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate; 7-(2-Amino-2-phenyl-acetylamino)-3-chloro-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Pars planitis Approved [2]
Pneumonia CA40 Approved [2]
Respiratory tract infection CA45 Approved [2]
Staphylococcus aureus infection Approved [2]
Urinary tract infection GC08 Approved [2]
Therapeutic Class
Antibiotics
Cross-matching ID
PubChem CID
51039
ChEBI ID
CHEBI:3478
CAS Number
CAS 53994-73-3
TTD Drug ID
DMJXDGC
VARIDT Drug ID
DR00259
ACDINA Drug ID
D00104

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial Penicillin binding protein (Bact PBP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ampicillin DMHWE7P Acute epiglottitis Approved [10]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [11]
Ceftriaxone DMCEW64 Acute gonococcal cervicitis Approved [12]
Ticarcillin DM4ME02 Aspiration pneumonia Approved [13]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [14]
Meropenem DM62UHC Bacterial infection 1A00-1C4Z Approved [12]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [15]
Clofarabine DMCVJ86 Acute lymphoblastic leukaemia 2A85 Approved [16]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [17]
Carbenicillin DMLEDNK Infection of the upper and lower urinary tract GC08 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Peptide transporter 1 (SLC15A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [4]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [19]
Ampicillin DMHWE7P Acute epiglottitis Approved [20]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [21]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [22]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [23]
Ceftriaxone DMCEW64 Acute gonococcal cervicitis Approved [24]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [19]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [21]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Peptide transporter 2 (SLC15A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [4]
Ampicillin DMHWE7P Acute epiglottitis Approved [25]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [26]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [27]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [28]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [25]
Valaciclovir DMHKS94 Genital herpes 1A94 Approved [29]
Aminolevulinic acid hci DMS4BLQ Acne vulgaris ED80 Approved [30]
Spirapril DM5XLTY Hypertension BA00-BA04 Approved [31]
Cefixime DMY60I8 Acute gonococcal cervicitis Approved [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporter 1 (SLC22A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [32]
Methotrexate DM2TEOL Anterior urethra cancer Approved [33]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [34]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [35]
Aciclovir DMYLOVR Genital herpes 1A94 Approved [35]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [35]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [36]
Olmesartan medoxomil DMWBHRY High blood pressure BA00 Approved [37]
Zalcitabine DMH7MUV Human immunodeficiency virus infection 1C62 Approved [38]
FLUORESCEIN DMQTFAO Ocular disease 1F00.1Z Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Organic anion transporter 3 (SLC22A8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [40]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [34]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [35]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [41]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [42]
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [43]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [44]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [45]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [46]
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [47]
Valsartan DMREUQ6 Chronic heart failure BD1Z Approved [48]
Methotrexate DM2TEOL Anterior urethra cancer Approved [49]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [50]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [41]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [51]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [51]
Cefdinir DMJ7A0H Bacterial infection 1A00-1C4Z Approved [7]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [52]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [53]
Quercetin DM3NC4M Obesity 5B81 Approved [54]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [55]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [56]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [57]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [58]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [59]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [59]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [60]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [61]
Capsaicin DMGMF6V Back pain ME84.Z Approved [62]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [64]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [8]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [8]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [65]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [64]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [8]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [66]
Gefitinib DM15F0X Colon adenocarcinoma Approved [64]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [67]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [64]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Binder [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [4]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [5]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [6]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [8]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [9]
Organic anion transporter 3 (SLC22A8) OT8BY933 S22A8_HUMAN Regulation of Drug Effects [7]

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062206.
2 Cefaclor FDA Label
3 Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74.
4 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
5 Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1. Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G895-902.
6 FDA Drug Development and Drug Interactions
7 Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
8 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
9 A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
10 Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
11 Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
14 Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
15 Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32.
16 Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
17 Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21.
18 Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23.
19 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
20 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
21 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
22 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
23 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
24 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
25 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
26 Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
27 The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
28 Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
29 Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
30 PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
31 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
32 The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
33 Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
34 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
35 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
36 Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
37 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
38 Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
39 Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
40 Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
41 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
42 Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
43 Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
44 Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
45 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
46 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
47 Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
48 Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. Toxicology. 2023 Jan 1;483:153387. doi: 10.1016/j.tox.2022.153387. Epub 2022 Dec 1.
49 P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016 Sep 1;306:27-35. doi: 10.1016/j.taap.2016.06.030. Epub 2016 Jul 1.
50 Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicol In Vitro. 2015 Feb;29(1):251-8. doi: 10.1016/j.tiv.2014.10.019.
51 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
52 Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
53 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
54 Potent Inhibitors of Organic Anion Transporters 1 and 3 From Natural Compounds and Their Protective Effect on Aristolochic Acid Nephropathy. Toxicol Sci. 2020 Jun 1;175(2):279-291. doi: 10.1093/toxsci/kfaa033.
55 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
56 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
57 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
58 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
59 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
60 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
61 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
62 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
63 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
64 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
65 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
66 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
67 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.